R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer in turn appoints Mikael Dolsten, an ex-Wyeth executive, as its worldwide R&D president.
You may also be interested in...
Facing Manufacturing Woes, Alexion Strengthens Leadership
Martin Mackay, who left AstraZeneca at the end of January after new CEO Pasqual Soriot eliminated his position as head of global R&D, is joining Alexion’s senior management team, even as the highly successful, rare disease-focused biotech seeks to put manufacturing woes behind it.
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.